Christopher Missling
Vorstandsvorsitzender bei ANAVEX LIFE SCIENCES CORP.
Vermögen: 4 Mio $ am 30.04.2024
Profil
Christopher U.
Missling is currently the President, CEO, Secretary & Director at Anavex Life Sciences Corp.
He previously held positions as the Chief Financial Officer at ImmunoGen, Inc., CFO & Senior Vice President-Strategic Operations at Curis, Inc., Head-Financial Planning at Aventis, Inc., and Head-Healthcare Investment Banking at Brimberg & Co. He has a graduate and doctorate degree from Ludwig-Maximilians-Universität München, an MBA from WHU-Otto Beisheim School of Management, and another MBA from Kellogg School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 28.03.2024 | 1 250 210 ( 1,52% ) | 4 Mio $ | 30.04.2024 |
Aktive Positionen von Christopher Missling
| Unternehmen | Position | Beginn |
|---|---|---|
| ANAVEX LIFE SCIENCES CORP. | Vorstandsvorsitzender | 05.07.2013 |
Ehemalige bekannte Positionen von Christopher Missling
| Unternehmen | Position | Ende |
|---|---|---|
| Aventis, Inc. | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Finanzdirektor/CFO | - |
Brimberg & Co.
 Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Corporate Officer/Principal | - |
| CURIS, INC. | Finanzdirektor/CFO | - |
Ausbildung von Christopher Missling
| Ludwig-Maximilians-Universität München | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
| WHU-Otto Beisheim School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| ANAVEX LIFE SCIENCES CORP. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
| Aventis, Inc. |
